TABLE 1.
Summary of Efficacy Data for a Range of PARP Inhibitors in Patients With mCRPC Comparing Outcomes in Those With Deleterious BRCA1 Versus BRCA2 Mutations
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.